nday
CVE-2026-100369 GHSA-j73w-8hfr-4gc9

CliInvoke: Argument Injection in Extensibility Runner Factory

alastairlundy / CliInvoke, AlastairLundy.CliInvoke

CVE 공개: . nday가 아직 패치 근거를 수집하지 않았습니다. 패치가 없다는 뜻은 아닙니다. PoC 출처 4곳 모두 미등재. CISA KEV 미등재.

why these tags

nday derives these tags by fixed rules from the facts below; NVD, the CNA and other sources do not assign them. Vocabulary and rules: ~/tags.

command injection
CWE-88, stated by the CNA GitHub_M 및 NVD, republishing [email protected]
local
AV:L in CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H (CVSS 3.1) from the CNA GitHub_M
no authentication required
PR:N in CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H (CVSS 3.1) from the CNA GitHub_M
no user interaction
UI:N in CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H (CVSS 3.1) from the CNA GitHub_M
현재 단계
DIS
공개
CVSS
8.4 HIGH v3.1

생명주기

가로축 UTC. 점 = 분 단위, 넓은 막대 = 날짜만, 빈 표시 = 불명 또는 추정.
시점 알 수 없음
DIS공개
09-25T20:26Z
PAT패치
아직 기록 없음
ANA분석
아직 기록 없음
POCPoC
아직 기록 없음
ITW악용
아직 기록 없음
KEVKEV
아직 기록 없음

요약

CliInvoke and its formerly named AlastairLundy.CliInvoke package are .NET libraries for invoking command-line programs and wrapping executable processes. CliInvoke versions 2.0.0 through 2.8.4, 2.9.0 through 2.9.3, 2.10.0 through 2.10.4, and 3.0.0-alpha.1 through 3.0.0-beta.1, as well as AlastairLundy.CliInvoke versions 2.0.0-alpha.1 through 2.0.0, contain an argument-injection vulnerability in RunnerProcessFactory on the 2.x line and RunnerConfigurationFactory on the 3.x line. These factories combine runner arguments, a caller-controlled target, and caller-controlled arguments into one ProcessStartInfo.Arguments string, allowing a double quote in the target or an argument to terminate an operating-system-level quoted region and inject unintended elements into the runner’s argument vector, potentially resulting in arbitrary command execution when a shell runner is used. The vulnerability is patched in CliInvoke versions 2.8.5, 2.9.4, 2.10.5, and 3.0.0-beta.2, and in AlastairLundy.CliInvoke version 2.0.2. No complete workaround is available; users unable to upgrade can partially mitigate the issue by removing double quotes from targets and arguments, additionally removing shell metacharacters when using shell runners, or bypassing the vulnerable factory and constructing a ProcessConfiguration with an explicit ArgumentList.

Original text of the CVE record (cvelist), shown as published.

Exploit conditions

What an attack needs, read from the CVSS vector.
Attack vector AV:L
Local: needs a local or SSH session, or a user tricked into acting on the machine
Attack complexity AC:L
Low: no special conditions; the attacker can expect repeatable success
Privileges required PR:N
None: no account or authorization needed
User interaction UI:N
None: no action by anyone other than the attacker

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

CVSS 3.1 vector from the CVE record, scored by the CNA GitHub_M.

이벤트 로그

+DISCVE 공개

CVE 레코드 공개(CNA: GitHub_M). CVSS 8.4(높음).

출처 cvelist · nday 일괄 수집 · 원본
{
  "id": 458689,
  "type": "disclosed",
  "source": "cvelist",
  "url": "https://www.cve.org/CVERecord?id=CVE-2026-100369",
  "occurred_at": "2026-09-25T20:26:51.352Z",
  "observed_at": "2026-11-13T05:40:22.207467Z",
  "is_backfill": true,
  "dedupe_key": "",
  "detail": {
    "cvss": {
      "source": "cna",
      "vector": "CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H",
      "version": "3.1",
      "base_score": 8.4,
      "base_severity": "HIGH"
    },
    "ssvc": {
      "timestamp": "2026-09-28T13:42:51.617325Z",
      "automatable": "no",
      "exploitation": "none",
      "technical_impact": "total"
    },
    "state": "PUBLISHED",
    "date_published": "2026-09-25T20:26:51.352Z",
    "assigner_short_name": "GitHub_M"
  }
}

Report an error

report an error or omission

Something on this page wrong or missing? Tell the editors; if they accept it, this page's revision log says so publicly. Upstream data is not changed.

연구자 논의

최근 7일간 연구자 0명이 언급

목록의 연구자가 X에서 이 CVE를 언급한 게시물입니다. 원문 그대로 보여 주며 nday는 검증하지 않습니다.

명단의 연구자가 X에서 이 CVE를 언급한 게시물은 아직 수집되지 않았습니다.

Discussion

0 comments

No comments yet.